
    
      The investigators propose to use the adverse effects as well as the need for dose reduction
      as a criterion to judge tolerability of treatment.

      The primary endpoint would be hematological response rate according to international myeloma
      working group (IMWG) response criteria for amyloidosis and neurological response rate defined
      by overall neuropathy limitation scale (ONLS) score.

      This study expects to enroll approximately 41 subjects.
    
  